Small Intestine Cancer Clinical Trial
Official title:
Assessment of an Optimized and Standardized Computerised Tomography (CT) Reading Grid for Preoperative Planning Improvement of Small Bowel Neuroendocrine Tumours (NET).
Neuro-endocrine tumours (NET) are the most frequent tumours of the small intestine. In spite
of their small size, these tumours have the particularity of forming mesenteric metastasis
and ganglionic secondary lesions along the superior mesenteric axis, which is in close
proximity to the superior mesenteric artery (SMA).
Surgery is the only curative treatment. The complete resection being a factor for good
patient prognosis, risks of subsequent local complications (occlusion, bleeding) must be
discussed. The limiting factor for resectability is arterial vascular invasion considering
the risk of postoperative small bowel syndrome.
At the moment, the choice of imaging examination and its protocol is not standardized, nor
the description of the tumoral mesenteric and ganglionic extension, especially the criteria
defining a lymph node as lymphadenopathy. In addition, the complexity of SMA's anatomy and
the absence of criteria for arterial invasion defining arterial invasion may lead to a
misinterpretation of the preoperative imaging , and thus to an incomplete planning of the
surgical procedure.
To correct this absence of radiological standardization, the investigating team has developed
a reading grid for Computed Tomography (CT) aimed to facilitate preoperative planning of
small bowel NET.
The main objective of the current study is to improve the semiotic description of the
mesenteric and ganglionic tumoral extension of small intestine NET using a technically
optimized imaging examination and a standardized reading grid in order to plan the best
surgical procedure which would allow maintaining a minimal length of small intestine needed
to yield a satisfying quality of life and nutritional status.
The secondary objective of this study is to evaluate the reproducibility of the standardized
scanner's reading grid.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT00903396 -
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
|
Phase 2 | |
| Terminated |
NCT00896467 -
Psychological and Emotional Impact in Patients Undergoing Treatment For Metastatic Cancer Either in a Clinical Trial or as Standard Off-Trial Therapy
|
N/A | |
| Completed |
NCT00897923 -
Imaging of Radiolabeled White Blood Cells in Patients With Non-Hodgkin's Lymphoma
|
N/A | |
| Completed |
NCT00003993 -
Bryostatin 1 and Interleukin-2 in Treating Patients With Refractory Solid Tumors or Lymphoma
|
Phase 1 | |
| Recruiting |
NCT04907643 -
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
|
N/A | |
| Completed |
NCT00956475 -
Quality of Life in Younger Leukemia and Lymphoma Survivors
|
Phase 1 | |
| Completed |
NCT00646139 -
KX2-391 in Treating Patients With Advanced Solid Tumors or Lymphoma That Did Not Respond to Treatment
|
Phase 1 | |
| Active, not recruiting |
NCT00410462 -
Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma
|
Phase 2 | |
| Completed |
NCT00562380 -
AMG-479 in Treating Patients With Advanced Solid Tumors or Non-Hodgkin Lymphoma
|
Phase 1 | |
| Completed |
NCT00049400 -
S0355 Ixabepilone in Treating Patients With Advanced Solid Tumors or Lymphomas and Liver Dysfunction
|
Phase 1 | |
| Completed |
NCT00049712 -
Monoclonal Antibody Therapy in Treating Patients With Refractory Advanced Solid Tumors or Lymphoma
|
Phase 1 | |
| Completed |
NCT00049699 -
VNP40101M in Treating Patients With Advanced or Metastatic Cancer
|
Phase 1 | |
| Completed |
NCT00006348 -
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
|
Phase 3 | |
| Completed |
NCT00005804 -
Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
|
Phase 2 | |
| Completed |
NCT00004189 -
Rebeccamycin Analog and Cisplatin With or Without Filgrastim in Treating Patients With Advanced Cancer
|
Phase 1 | |
| Completed |
NCT00004895 -
Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery
|
Phase 2 | |
| Completed |
NCT00004904 -
Stem Cell Transplantation in Treating Patients With Hematologic Cancer
|
Phase 1 | |
| Completed |
NCT00019019 -
Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas
|
Phase 1 | |
| Withdrawn |
NCT00621036 -
Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma
|
Phase 2 | |
| Completed |
NCT00987766 -
Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer
|
Phase 1 |